We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$502M
AUM Growth
+$123M
Cap. Flow
+$124M
Cap. Flow %
24.65%
Top 10 Hldgs %
77.67%
Holding
30
New
5
Increased
16
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$35.7M
2
ARGX icon
argenx
ARGX
+$28.6M
3
INCY icon
Incyte
INCY
+$24.4M
4
BCYC
Bicycle Therapeutics
BCYC
+$22.1M
5
UTHR icon
United Therapeutics
UTHR
+$17.8M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$13.3M
5
PRTA icon
Prothena Corp
PRTA
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
26
Kymera Therapeutics
KYMR
$8.51B
– –
-227,034
Closed -$9.61M
PRTA icon
27
Prothena Corp
PRTA
$425M
– –
-267,946
Closed -$9.8M
ZNTL icon
28
Zentalis Pharmaceuticals
ZNTL
$337M
– –
-287,577
Closed -$13.3M
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-910,416
Closed -$15.3M
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-136,243
Closed -$14.3M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Paradigm Biocapital Advisors held 30 positions worth $502M, up 33% from $378M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Paradigm Biocapital Advisors deployed $124M of net new capital in Q2 2022, opening 5 new positions and adding to 16 existing holdings. Its largest new stake was argenx: 88,816 shares worth $33.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was C4 Therapeutics, an estimated $3.75M trimmed.

  • Paradigm Biocapital Advisors's largest Q2 2022 buy was argenx: 88,816 shares worth $33.7M.
  • Paradigm Biocapital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2022, an estimated $35.7M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2022 reduction was C4 Therapeutics, cutting an estimated $3.75M.
  • Paradigm Biocapital Advisors fully exited IVERIC bio, Inc. Common Stock in Q2 2022, selling an estimated $15.3M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 78% of its $502M portfolio in Q2 2022.
  • Paradigm Biocapital Advisors opened 5 new positions and closed 7 in Q2 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 33% quarter-over-quarter to $502M.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.